Advice
following a full submission:
sucroferric oxyhydroxide (Velphoro®) is accepted for use within NHS Scotland.
Indication under review: For the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). It should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.
After 12 weeks, sucroferric oxyhydroxide was non-inferior to a non-calcium, non-aluminium-based phosphate binder at lowering serum phosphorus levels in adults with CKD, receiving HD or PD.
Download detailed advice209KB (PDF)
Medicine details
- Medicine name:
- sucroferric oxyhydroxide (Velphoro)
- SMC ID:
- 1035/15
- Indication:
- For the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). It should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.
- Pharmaceutical company
- Fresenius Medical Care (UK) Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 April 2015